×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:MREO

Mereo BioPharma Group News Headlines

$1.53
+0.12 (+8.51%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.25
$1.62
50-Day Range
$0.33
$1.69
52-Week Range
$0.30
$3.31
Volume
7.91 million shs
Average Volume
11.87 million shs
Market Capitalization
$178.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Get Mereo BioPharma Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.

MREO Media Mentions By Week

MREO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MREO
News Sentiment

1.24

0.39

Average
Medical
News Sentiment

MREO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MREO Articles
This Week

1

0

MREO Articles
Average Week



MREO Stock News Headlines Today

SourceHeadline
finance.yahoo.com logoMereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout
finance.yahoo.com - June 20 at 12:35 PM
MarketBeat logoMereo BioPharma Group (NASDAQ:MREO) Price Target Cut to $5.00
americanbankingnews.com - June 8 at 2:48 AM
finance.yahoo.com logoMereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan
finance.yahoo.com - June 2 at 9:57 AM
MarketBeat logoMereo BioPharma Group (NASDAQ:MREO) Downgraded by Zacks Investment Research
americanbankingnews.com - June 2 at 4:06 AM
finance.yahoo.com logoMereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 26 at 9:20 PM
finance.yahoo.com logoMereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors
finance.yahoo.com - May 17 at 9:11 AM
seekingalpha.com logoMereo Biopharma stock rises as alvelestat high dose shows promise in lung disease in phase 2 trial
seekingalpha.com - May 9 at 9:52 AM
finance.yahoo.com logoMereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema
finance.yahoo.com - May 9 at 9:52 AM
finance.yahoo.com logoMereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat
finance.yahoo.com - May 6 at 7:33 PM
finance.yahoo.com logoMereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat
finance.yahoo.com - May 6 at 7:33 PM
finance.yahoo.com logoMEREO BIOPHARMA (MREO) Loses 38.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
finance.yahoo.com - April 22 at 2:19 PM
finance.yahoo.com logoMereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 6 at 9:26 AM
finance.yahoo.com logoMereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights
finance.yahoo.com - March 31 at 4:16 PM
finance.yahoo.com logoMereo BioPharma to Hold Virtual R&D Day on Monday, March 14, 2022
finance.yahoo.com - March 3 at 4:46 PM
finance.yahoo.com logoMereo BioPharma to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 10 at 5:49 PM
nasdaq.com logoMereo BioPharma Group plc American Depositary Shares (MREO)
nasdaq.com - January 20 at 10:47 PM
nasdaq.com logoMereo Biopharma Group Plc - ADR Shares Near 52-Week Low - Market Mover
nasdaq.com - January 10 at 7:44 AM
bizjournals.com logoUAB and Mereo BioPharma Group post positive results from Covid-19 clinical trial
bizjournals.com - December 29 at 1:45 AM
marketwatch.com logoMereo BioPharma Sees Positive Results in Trial for Covid-19 Treatment
marketwatch.com - December 22 at 7:47 AM
finance.yahoo.com logoUAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease
finance.yahoo.com - December 22 at 7:47 AM
benzinga.com logoBiomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereo's Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting
benzinga.com - December 14 at 7:27 AM
finance.yahoo.com logoBiomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereo’s Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting
finance.yahoo.com - December 13 at 10:10 AM
finance.yahoo.com logoMereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors
finance.yahoo.com - November 30 at 8:22 AM
finance.yahoo.com logoMereo BioPharma to Present at Two Upcoming Investor Conferences
finance.yahoo.com - November 9 at 10:37 AM
finance.yahoo.com logoData from Investigator-sponsored Trial of Mereo BioPharma’s alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 4 at 11:29 AM
finance.yahoo.com logoMereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency
finance.yahoo.com - October 26 at 8:31 AM
nz.finance.yahoo.com logoGlobal Partner Relationship Management Market (2021 to 2027) - by Component, Deployment Type, Enterprise Size, End-user and Region
nz.finance.yahoo.com - October 15 at 12:02 AM
finance.yahoo.com logoMereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) announces completion of the IMPACT Survey enrollment
finance.yahoo.com - October 13 at 9:41 AM
finance.yahoo.com logoMereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors
finance.yahoo.com - September 20 at 10:07 AM
finance.yahoo.com logoMereo BioPharma to Participate in Three Upcoming Investor Conferences
finance.yahoo.com - September 9 at 12:18 PM
finance.yahoo.com logoHedge Funds Are Crazy About Mereo BioPharma Group plc (MREO)
finance.yahoo.com - July 19 at 10:22 PM
finance.yahoo.com logoMereo's Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome
finance.yahoo.com - June 2 at 2:37 PM
finance.yahoo.com logoMereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)
finance.yahoo.com - June 2 at 9:36 AM
finance.yahoo.com logoMereo BioPharma to Participate in a Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference
finance.yahoo.com - May 27 at 9:51 AM
finance.yahoo.com logoMereo BioPharma to Hold Virtual R&D Day on Thursday, May 13, 2021
finance.yahoo.com - May 4 at 8:14 AM
feeds.benzinga.com logoCancer Focus Fund To Finance Mereo's Ovarian Cancer Study With Etigilimab
feeds.benzinga.com - April 30 at 10:27 AM
finance.yahoo.com logoMereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 8 at 1:13 PM
finance.yahoo.com logoMereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 18 at 9:46 AM
finance.yahoo.com logoMereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
finance.yahoo.com - February 12 at 1:12 PM
benzinga.com logoMereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development
benzinga.com - November 23 at 7:21 AM
finance.yahoo.com logoMereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020
finance.yahoo.com - November 16 at 8:01 AM
finance.yahoo.com logoMereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs
finance.yahoo.com - October 20 at 8:03 AM
finance.yahoo.com logoMereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update
finance.yahoo.com - October 14 at 3:09 AM
benzinga.com logoMereo BioPharma Announces Interim Financial...
benzinga.com - September 29 at 12:30 PM
seekingalpha.com logoMereo BioPharma Group reports 1H results, corporate update
seekingalpha.com - September 29 at 12:30 PM
seekingalpha.com logoMereo BioPharma's (MREO) CEO Denise Scots-Knight on 2020 Interim Financial Results Conference Call Transcript
seekingalpha.com - September 29 at 12:30 PM
finance.yahoo.com logoMereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta
finance.yahoo.com - September 24 at 7:23 AM
finance.yahoo.com logoMereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2020 and Host Conference Call on September 29, 2020
finance.yahoo.com - September 16 at 8:08 AM
finance.yahoo.com logoBillionaire Steven Cohen Pulls the Trigger on These 3 Penny Stocks
finance.yahoo.com - August 17 at 4:20 PM
www.reuters.com logoBRIEF-Mereo Biopharma Group Files For Offering Of Up To 103.1 Million Adss By The Selling Shareholders
www.reuters.com - July 7 at 12:43 AM
Get Mereo BioPharma Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:MREO) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.